Long-term impact of anthracycline in early-stage breast cancer, bridging of MiRNAs profiler for early cardiotoxicity

• DOI: 10.1186/s40959-025-00337-2
• Publication Date: 2025-04-23T08:51:45Z
• Authors: Nattaya Poovorawan; Thiti Susiriwatan...; Chinachote Teerap...; Pajaree Chariyavi...; Piyada Sitthideat...; Luxica Jarutasnan...; Monravee Tumkosit; Pairoj Chattranuk...; Nonthikorn Theera...; Chatchawit Apornt...; Shanop Shuangshoti; Sopark Manasnayakorn; Chanida Vinayanuw...; Yongkasem Voraset...; Virote Sriuranpong
• Keywords: Cardiotoxicity

Anthracyclines are essential in early breast cancer chemotherapy but pose long-term cardiotoxicity risks. This study aims to investigate the incidence of therapy-related cardiac dysfunction (CTRCD), bridging with miRNAs profiler representing acute injury. We conducted a prospective cohort including stage I-III patients who received anthracycline between 2007 and 2012. Echocardiography was performed before 12 weeks after administration. The by NanoString RT-PCR. Long-term magnetic resonance imaging (CMR) evaluated 24.2% asymptomatic participants. At median follow-up 11 [IQR 6-12] years, 194 completed echocardiography were included analysis. age at diagnosis 50 [26-72] years. An LVEF decline ≥ 10% found 32.9% cumulative equivalent dose doxorubicin 223.2 ± 21.6 mg/m2. time censoring, sixty-four participants (32.9%) died, 70% from cancer. Nine (4.6%) reported cardiovascular events compatible CTRCD definition. Forty-seven (24.2%) underwent evaluation. RT-PCR different points, 3 6 weeks, respectively, revealed significantly diverse expressions miR-1-3p miR-16-5p without an 10%. Despite injury demonstrated dynamic miR-16-5p, CMR parameters no significant differences. Our demonstrates very low symptomatic CTRCD. expression patterns points also provide valuable biological insights. Within-normal results exact comprehensive CMR, any change participants, indicate safety limited-dose anthracycline-containing use.